What topics does this cannabis study cover?

This study covers research on: THC, CBD, Inflammation, Endocannabinoid.

Where was this research published?

Published in La Revue de medecine interne on July 10, 2026.

Cannabinoids may calm immune activity, but evidence remains limited

Q: What did this Review find?

*Cannabinoids* may have **anti-inflammatory and analgesic effects**, with established symptomatic uses including neuropathic pain, epilepsy, and spasticity associated with multiple sclerosis.

[Clinical immunomodulatory effects of cannabinoids in autoimmune diseases in internal medicine : A literature review].

La Revue de medecine interne • July 10, 2026 • Review • Highly Relevant

🤖

AI Summary

This literature review examines how cannabis-derived compounds may influence the immune system in autoimmune disease. It describes the endocannabinoid system, including CB1 receptors found mainly in the nervous system and CB2 receptors expressed notably by immune cells and the spleen. The main phytocannabinoids, THC and CBD, are linked to effects such as reduced inflammation, pain relief, and altered neurotransmitter release. Cannabinoid-based medicines are currently used mainly to manage symptoms including multiple-sclerosis spasticity, neuropathic pain, and epilepsy.

Laboratory and human evidence suggests cannabinoids can inhibit the multiplication of CD4+ T cells and B cells and encourage a shift toward a Th2 immune profile, associated with lower production of pro-inflammatory cytokines. However, the review emphasizes that clinical research in autoimmune diseases remains scarce, and the available evidence is heterogeneous. No quantitative results are reported in the abstract, so cannabinoids should not be viewed as established treatments for autoimmune disease; further basic and clinical research is needed to clarify their benefits, risks, and appropriate use.

💡 Key Findings

Cannabinoids may have anti-inflammatory and analgesic effects, with established symptomatic uses including neuropathic pain, epilepsy, and spasticity associated with multiple sclerosis.

Good

70%

The review reports that cannabinoids can inhibit the proliferation of CD4+ T cells and B cells and promote a Th2 shift linked to reduced pro-inflammatory cytokine production.

Good

60%

Clinical evidence for cannabinoid treatment in autoimmune diseases remains scarce and heterogeneous, so therapeutic implications are not yet established.

High

80%

The findings support the need for further basic and clinical research before cannabinoids can be reliably recommended for autoimmune disease management.

High

80%

📄 Original Abstract

Cannabis has been used for nearly five millennia for its medicinal properties. The endocannabinoid system and the pharmacology of the main phytocannabinoids (Δ9-tetrahydrocannabinol, cannabidiol) were characterized between the 1970s and 1990s. Two types of cannabinoid receptors have been identified: type 1 receptors, primarily located in the central and peripheral nervous systems, and type 2 receptors, expressed notably by immune cells and the spleen (type 2). The development of cannabinoid-derived drugs, such as dronabinol, nabiximols, and cannabidiol, is based on two main principles: their role in modulating the release of presynaptic neurotransmitters and their anti-inflammatory and analgesic effects, demonstrated in experimental models and in humans. These treatments are currently used primarily for the symptomatic management of spasticity associated with multiple sclerosis, neuropathic pain, and epilepsy. From an immunological perspective, cannabinoids exert complex effects, including inhibition of CD4+ T-cell and B-cell proliferation, as well as a shift toward a Th2 profile, associated with reduced production of pro-inflammatory cytokines. However, clinical studies evaluating their effects in autoimmune diseases remain scarce. The available, heterogeneous data underscore the need for further basic and clinical research to better characterize these mechanisms and their therapeutic implications.